STO · SPERM.ST
Spermosens AB
SEK 0.01+SEK 0.00 (+6.98%)
Spermosens AB’s quoted price sits in the upper half of its reported 52-week range, 23.33% below the high.
Loading market information…
STO · FLUI.ST · SEK
Stock price, earnings
Quote as of Oct 30, 2026, 08:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Fluicell AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 58.78% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Fluicell AB (publ)’s next earnings report is currently expected on Nov 13, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Fluicell AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic systems, engineered for precise localized solution delivery during single-cell experiments and for managing the chemical microenvironment of individual intact cells within tissue or cell cultures. Furthermore, Fluicell offers the Dynaflow Resolve system, a specialized platform for secondary ion channel screening that enables the measurement of various ion channel currents in a patch-clamp recording configuration. This Swedish company, headquartered in Gothenburg, was founded in 2012.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 0.01+SEK 0.00 (+6.98%)
Spermosens AB’s quoted price sits in the upper half of its reported 52-week range, 23.33% below the high.
SEK 1.47SEK 0.00 (0.0%)
Guard Therapeutics International AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 94.56% below the high.
SEK 1.33-SEK 0.04 (-2.92%)
ODI Pharma AB’s quoted price sits in the lower half of its reported 52-week range, 75.6% below the high.
SEK 0.21SEK 0.00 (0.0%)
Stayble Therapeutics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 68.27% below the high.
SEK 0.42-SEK 0.06 (-12.13%)
2cureX AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 87.16% below the high.
SEK 0.27SEK 0.00 (0.0%)
Aptahem AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 86.21% below the high.
SEK 0.11-SEK 0.00 (-0.93%)
Prostatype Genomics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 95.35% below the high.
SEK 0.02SEK 0.00 (0.0%)
LIDDS AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 87.7% below the high.
